Etanercept as a salvage treatment for refractory aplastic anemia

Carlo Dufour, Raffaella Giacchino, Pietro Ghezzi, Rossella Tonelli, Elisa Ferretti, A. Pitto, Vito Pistoia, Tiziana Lanza, Johanna Svahn

Research output: Contribution to journalArticlepeer-review


About 10-15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.

Original languageEnglish
Pages (from-to)522-525
Number of pages4
JournalPediatric Blood and Cancer
Issue number4
Publication statusPublished - Apr 2009


  • Anti-TNF
  • Complicated aplastic anemia
  • HCV infection

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)


Dive into the research topics of 'Etanercept as a salvage treatment for refractory aplastic anemia'. Together they form a unique fingerprint.

Cite this